文献速递免疫规划

台湾地区2020/21流感季节四价重组流感疫苗全国安全性监测

National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21.
PubMed 文献 · Vaccine · 2022-05-14

台湾地区在2020-2021流感疫苗接种季通过特别进口采购了35万剂四价重组流感疫苗(RIV4,Flublok Quadrivalent),并利用国家被动监测系统收集2021年1月至7月的不良事件报告。在200,287剂接种中报告8例不良事件,报告率为每10万剂3.99例,其中6例为非严重事件,2例被列为严重事件但均判定与接种无因果关系,结论支持RIV4在台湾人群中的安全性。

要点

  • 200,287剂RIV4接种中报告8例不良事件,报告率为每10万剂3.99例。
  • 8例中6例(75%)为非严重事件,最常见为红斑性皮疹伴瘙痒。
  • 2例被列为严重事件,但均判定与RIV4接种无因果关系。

核心结论

  • 台湾地区国家被动监测数据支持四价重组流感疫苗(RIV4)在台湾人群中的安全性。

研究设计与样本

  • 利用台湾地区国家药品不良反应通报系统,收集2021年1月至2021年7月(RIV4接种后至少一个月)的不良事件报告,基于总接种剂次计算报告率。

主要发现

  • 在200,287剂接种中报告8例不良事件,报告率为每10万剂3.99例。
  • 报告个体平均年龄为47.53岁,女性占75%。
  • 多数不良事件在接种后第一天内开始,其中1例报告在接种后4天开始。
  • 8例中75%(n=6)为非严重事件,最常见症状为红斑性皮疹伴瘙痒。
  • 2例基于「其他临床显著医学情况」标准被列为严重事件,但均判定与RIV4接种无因果关系。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During the COVID-19 pandemic, the need for influenza vaccine significantly increased in the initial weeks of the 2020-2021 influenza vaccination campaign season in Taiwan. To meet this demand, the Taiwanese government therefore purchased additional influenza vaccines via special import, including 350,000 doses of quadrivalent recombinant influenza vaccines (RIV4, Flublok Quadrivalent). Approved in the United States since 2016, there were limited numbers of published studies regarding RIV4 outside America. We utilized the national passive surveillance system consisting adverse event (AE) reports following RIV4 immunization to describe its safety profiles in Taiwan. METHODS: We obtained the database from the Taiwan National Adverse Drugs Reactions Reporting System and collected reports from January 2021 to July 2021, which was at least one month after RIV4 immunization. AE reporting rates were calculated based on the total administered doses. RESULTS: Eight AEs were reported among 200,287 administered doses, which led to a reporting rate of 3.99 AEs per 100,000 doses administered. The mean age of the reported individuals were 47.53 years, and women (75%) were the predominant gender. Most adverse events started within the first day after immunization, with one reported as starting 4 days after vaccination. Among the 8 cases, 75% (n = 6) were non-serious and the most common symptoms were erythematous skin rashes with pruritus. Two cases were listed as serious based on the criteria of "other clinically significant medical conditions", but neither was judged to have a causal relationship with RIV4 immunization. CONCLUSION: The Taiwan national passive surveillance data supported the safety profiles of RIV4 in Taiwan population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tsai SY, Yeh TY, Chiu NC, et al. National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21. Vaccine. 2022. PMID: 35577629. doi:10.1016/j.vaccine.2022.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。